<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198129</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0640</org_study_id>
    <nct_id>NCT04198129</nct_id>
  </id_info>
  <brief_title>The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures</brief_title>
  <official_title>The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if postoperative antibiotic use in patients with
      mandible trauma reduce the risk of postoperative infections and does the benefit differ based
      on severity, soft tissue loss, other concomitant injuries, and medical problems
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of persistent swelling,</measure>
    <time_frame>post treatment week1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of persistent swelling,</measure>
    <time_frame>post treatment week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of persistent swelling,</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of fever</measure>
    <time_frame>post treatment week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of fever</measure>
    <time_frame>post treatment week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of fever</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of recurrent swelling</measure>
    <time_frame>post treatment week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of recurrent swelling</measure>
    <time_frame>post treatment week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of recurrent swelling</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of erythema</measure>
    <time_frame>post treatment week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of erythema</measure>
    <time_frame>post treatment week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of erythema</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of purulent discharge</measure>
    <time_frame>post treatment week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of purulent discharge</measure>
    <time_frame>post treatment week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of infection as measured by presence of purulent discharge</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of persistent swelling</measure>
    <time_frame>post treatment week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of persistent swelling</measure>
    <time_frame>post treatment week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of persistent swelling</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of fever</measure>
    <time_frame>post treatment week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of fever</measure>
    <time_frame>post treatment week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of fever</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of recurrent swelling</measure>
    <time_frame>post treatment week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of recurrent swelling</measure>
    <time_frame>post treatment week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of recurrent swelling</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of erythema</measure>
    <time_frame>post treatment week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of erythema</measure>
    <time_frame>post treatment week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of erythema</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of purulent discharge</measure>
    <time_frame>post treatment week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of purulent discharge</measure>
    <time_frame>post treatment week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of infection as measured by absence of purulent discharge</measure>
    <time_frame>post treatment week 6-8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Jaw Fractures</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic treatment (Unasyn or Clindamycin)</intervention_name>
    <description>Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic treatment (Augmentin or Clindamycin)</intervention_name>
    <description>the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All mandible fracture patients planned for Open Reduction and Internal Fixation (ORIF)

        Exclusion Criteria:

          -  Age - &lt; 18 years

          -  Pregnancy

          -  Fracture Site - closed / non-dentate eg. Condylar neck, edentulous

          -  Soft Tissue Injury - &gt; Grade 4 (GSW)

          -  Allergic to all study drugs

          -  Medical Problems

               1. Diabetes - Hb A1C &gt; 10

               2. Immunologic compromise

               3. On Chemotherapy

          -  Interval - Injury to Surgery - &gt; 10days

          -  Already receiving antibiotics for

               1. Another wound eg. Open fracture prophylaxis

               2. Documented / suspected infection

          -  Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagi Demian, DDS/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nagi Demian, DDS/MD</last_name>
    <phone>713-500-5082</phone>
    <email>Nagi.Demian@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Martinez</last_name>
    <phone>713-500-5082</phone>
    <email>Donna.M.Martinez@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nagi Demian, DDS/MD</last_name>
      <phone>713-500-5082</phone>
      <email>Nagi.Demain@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Donna Martinez</last_name>
      <phone>713-500-5082</phone>
      <email>Donna.M.Martinez@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Nagi Demian</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>Jaw fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mandibular Fractures</mesh_term>
    <mesh_term>Jaw Fractures</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

